Objective: Between September 2002 and February 2003, the authors assessed the effectiveness of a new, age-tailored, self-help smoking-cessation program for college students.
Participants: College student smokers (N = 216) from 6 Ontario universities participated.
Methods: The researchers used a randomized controlled trial with a 3-month telephone follow-up. Interventions included a new program (Smoke|Quit), the Canadian Cancer Society's self-help program, and a usual care quit kit.
Results: Intention-to-treat analysis of 7-day point prevalence cessation revealed quit rates of 11.4% for Smoke|Quit, 2.9% for the Cancer Society's program, and 5.6% for the usual care intervention (p < .05). Among nonquitters, 46.5% had made a quit attempt, and weekly consumption decreased from 54.01 to 42.08 cigarettes (p < .001) with no differences across interventions.
Conclusions: Making tailored, self-help programs widely available on campus may be an effective way to provide smoking-cessation support to a large segment of the young adult population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3200/JACH.57.4.437-444 | DOI Listing |
JAMA Netw Open
January 2025
Department of Pediatrics, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York.
Importance: Pediatric obesity and hypertension are highly correlated. To mitigate both conditions, provision of counseling on nutrition, lifestyle, and weight to children with high blood pressure (BP) measurements is recommended.
Objective: To examine racial and ethnic disparities in receipt of nutrition, lifestyle, and weight counseling among patients with high BP at pediatric primary care visits stratified by patients' weight status.
JMIR Aging
January 2025
The Medical Record Statistics Department, Zhejiang Hospital, Hangzhou, China.
Sports Med
January 2025
Department of Nutrition, China Medical University, Taichung, Taiwan.
Background: Diastasis recti abdominis (DRA), commonly occurring in postpartum women, is not only an aesthetic issue but is also highly associated with functional impairments. Various conservative treatment modalities have been employed in clinical practice to alleviate DRA. However, the comparative efficacy of these non-surgical treatments for improving the inter-recti distance (IRD) remains to be determined.
View Article and Find Full Text PDFClin Oral Investig
January 2025
Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Clinical Research Center for Oral Diseases of Zhejiang Province, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Objectives: To evaluate recent advances in the automatic multimodal registration of cone-beam computed tomography (CBCT) and intraoral scans (IOS) and their clinical significance in dentistry.
Methods: A comprehensive literature search was conducted in October 2024 across the PubMed, Web of Science, and IEEE Xplore databases, including studies that were published in the past decade. The inclusion criteria were as follows: English-language studies, randomized and nonrandomized controlled trials, cohort studies, case-control studies, cross-sectional studies, and retrospective studies.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!